Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma

Journal of the American Animal Hospital Association

Volumn 39, Issue 5, 2003, Pages 463-467

  Jones, Pamela D ^a   de Lorimier, Louis Philippe ^a   Kitchell, Barbara E ^a   Losonsky, John M ^a  

^a Veterinary Teaching Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN DERIVATIVE; ETANIDAZOLE; GEMCITABINE; LIPOSOME; MITOXANTRONE; RADIOSENSITIZING AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CAT; CONTROLLED STUDY; DOSE RESPONSE; LOW DRUG DOSE; MEGAVOLTAGE RADIOTHERAPY; MOUTH CARCINOMA; NONHUMAN; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

FELIDAE; FELIS CATUS;

EID: 0141731181     PISSN: 05872871     EISSN: None     Source Type: Journal    
DOI: 10.5326/0390463     Document Type: Article

References (32)

1. Cotter SM. Oral pharyngeal neoplasms in the cat. J Am Anim Hosp Assoc 1981;17:917-920.
2. Withrow SJ. Cancer of the gastrointestinal tract. In: Withrow SJ, MacEwan EG, eds. Small animal clinical oncology. Philadelphia: WB Saunders, 2001:305-318.
3. Ogilvie GK, Moore AS, eds. Managing the veterinary cancer patient. New Jersey: Veterinary Learning Systems, 1995:340-343.
4. Stebbins KE, Morse CC, Goldschmidt MH. Feline oral neoplasia: a ten-year survey. Vet Pathol 1989;26:121-128.
5. Postorino Reeves NC, Turrel JM, Withrow SJ. Oral squamous cell carcinoma in the cat. J Am Anim Hosp Assoc 1993;29:438-441.
6. Hutson CA, Willauer CC, Walder EJ, Stone JL, Klein MK. Treatment of mandibular squamous cell carcinoma in cats by use of mandibulectomy and radiotherapy: seven cases (1987-1989). J Am Vet Med Assoc 1992;201(5):777-781.
7. Fox LE, Rosenthal RC, King RR, et al. Use of cis-bis-neodecanoato-trans-R-R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. Am J Vet Res 2000;61(7):791-795.
8. Evans SM, LaCreta F, Helfand S, et al. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma. Int J Rad Oncol Biol Phys 1991;20(4):703-708.
9. LaRue SM, Vail DM, Ogilvie GK, Powers BE, Withrow SJ. Shrinking-field radiation therapy in combination with mitoxantrone chemotherapy for the treatment of oral squamous cell carcinoma in the cat. Proceedings, 11th Ann Vet Canc Soc Conf, Oct 27-29, Minneapolis: 1991.
10. Ogilvie GK, Moore AS, Obradovich JE, et al. Toxicosis and efficacy associated with administration of mitoxantrone to cats with malignant tumors. J Am Vet Med Assoc 1993;202(11):1839-1844.
11. McEntee MC, Page RL, Novotney CA, Thrall DE. Palliative radiotherapy for canine appendicular osteosarcoma. Vet Rad & Ultrasound 1993;34(5):367-370.
12. Ramirez O, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Rad & Ultrasound 1999;40(4):517-522.
13. Thrall DE, LaRue SM. Palliative radiation therapy. Sem Vet Med Surg Sm Anim 1995;10(3):205-208.
14. Bregazzi VS, LaRue SM, Powers BE, Fettman MJ, Ogilvie GK, Withrow SJ. Response of feline oral squamous cell carcinoma to palliative radiation therapy. Vet Rad & Ultrasound 2001;42(1):77-79.
15. Doyle TH, Mornex F, McKenna WG. The clinical implications of gemcitabine radiosensitization. Clin Cancer Res 2001;7:226-228.
16. National Institutes of Health. Summary of BMT - specific adverse events. In: Common toxicity criteria - version 2.0, 1999:75.
17. Devriendt D, Klastersky J. New cytostatic agents for the treatment of head and neck cancer. Acta Oto-Rhino-Laryngologica Belg 1997;51:61-68.
18. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19(3):792-799.
19. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Sem Oncol 1997;24(2):S7-24-S7-28.
20. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by gemcitabine. Oncol 1999;13(10):S5-55-S5-60.
21. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996;14:257-263.
22. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncol 2002;62(1):2-8.
23. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anticanc Drugs 1998;9(3):191-201.
24. Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Canc Res Clin Oncol 1999;125(11):637-640.
25. Gietema JA, Groen HJ, Meijer S, Smit EF. Effects of gemcitabine on renal function in patients with non-small cell lung cancer. Eur J Canc 1998;34(1):199-202.
26. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 2000;18(14):2780-2787.
27. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small cell lung cancer. Int J Radiation Oncol Biol Phys 2001;51(5):1281-1289.
28. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19(22):4202-4208.
29. Benasso M, Merlano M, Sanguineti G, et al. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. Am J Clin Oncol 2001;24(6):618-622.
30. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Canc Res 2001;7(8):2246-2253.
31. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17(7):2208-2212.
32. Pipas JM, Mitchell SE, Barth Jr RJ, et al. Phase I study of twice-weekly gemcitabine with concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radia Oncol Biol Phys 2001;50(5):1317-1322.